<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/1226099#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction5" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction6" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep80">
 <bp:stepProcess rdf:resource="#Catalysis26" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction66" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction7" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction9" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction2" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis12">
 <bp:controlled rdf:resource="#BiochemicalReaction33" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep87">
 <bp:stepProcess rdf:resource="#BiochemicalReaction71" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis11">
 <bp:controlled rdf:resource="#BiochemicalReaction32" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep88">
 <bp:stepProcess rdf:resource="#Catalysis29" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction72" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis10">
 <bp:controlled rdf:resource="#BiochemicalReaction28" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep85">
 <bp:stepProcess rdf:resource="#Pathway16" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep86">
 <bp:stepProcess rdf:resource="#Pathway17" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction14" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep83">
 <bp:stepProcess rdf:resource="#Catalysis27" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction69" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction16" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep84">
 <bp:stepProcess rdf:resource="#Catalysis28" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction70" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis8">
 <bp:controlled rdf:resource="#BiochemicalReaction18" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep81">
 <bp:stepProcess rdf:resource="#BiochemicalReaction67" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis9">
 <bp:controlled rdf:resource="#BiochemicalReaction25" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep82">
 <bp:stepProcess rdf:resource="#BiochemicalReaction68" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep89">
 <bp:stepProcess rdf:resource="#Pathway18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep90">
 <bp:stepProcess rdf:resource="#BiochemicalReaction73" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep91">
 <bp:stepProcess rdf:resource="#BiochemicalReaction74" />
 <bp:stepProcess rdf:resource="#Catalysis30" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis23">
 <bp:controlled rdf:resource="#BiochemicalReaction62" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep98">
 <bp:stepProcess rdf:resource="#BiochemicalReaction80" />
 <bp:stepProcess rdf:resource="#Catalysis33" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis22">
 <bp:controlled rdf:resource="#BiochemicalReaction55" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep99">
 <bp:stepProcess rdf:resource="#BiochemicalReaction81" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis21">
 <bp:controlled rdf:resource="#BiochemicalReaction54" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep96">
 <bp:stepProcess rdf:resource="#Catalysis32" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction78" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis20">
 <bp:controlled rdf:resource="#BiochemicalReaction52" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep97">
 <bp:stepProcess rdf:resource="#BiochemicalReaction79" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep94">
 <bp:stepProcess rdf:resource="#Pathway19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep95">
 <bp:stepProcess rdf:resource="#BiochemicalReaction77" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep92">
 <bp:stepProcess rdf:resource="#BiochemicalReaction75" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep93">
 <bp:stepProcess rdf:resource="#BiochemicalReaction76" />
 <bp:stepProcess rdf:resource="#Catalysis31" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis19">
 <bp:controlled rdf:resource="#BiochemicalReaction50" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis18">
 <bp:controlled rdf:resource="#BiochemicalReaction47" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis17">
 <bp:controlled rdf:resource="#BiochemicalReaction44" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis16">
 <bp:controlled rdf:resource="#BiochemicalReaction43" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis15">
 <bp:controlled rdf:resource="#BiochemicalReaction42" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis14">
 <bp:controlled rdf:resource="#BiochemicalReaction38" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis13">
 <bp:controlled rdf:resource="#BiochemicalReaction34" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep43">
 <bp:stepProcess rdf:resource="#BiochemicalReaction35" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep44">
 <bp:stepProcess rdf:resource="#BiochemicalReaction36" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep41">
 <bp:stepProcess rdf:resource="#Catalysis12" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction33" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep42">
 <bp:stepProcess rdf:resource="#Catalysis13" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction34" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep40">
 <bp:stepProcess rdf:resource="#Catalysis11" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction32" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep49">
 <bp:stepProcess rdf:resource="#BiochemicalReaction41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep47">
 <bp:stepProcess rdf:resource="#BiochemicalReaction39" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep48">
 <bp:stepProcess rdf:resource="#BiochemicalReaction40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep45">
 <bp:stepProcess rdf:resource="#BiochemicalReaction37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep46">
 <bp:stepProcess rdf:resource="#BiochemicalReaction38" />
 <bp:stepProcess rdf:resource="#Catalysis14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep54">
 <bp:stepProcess rdf:resource="#BiochemicalReaction45" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep55">
 <bp:stepProcess rdf:resource="#BiochemicalReaction46" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep52">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep53">
 <bp:stepProcess rdf:resource="#Catalysis17" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction44" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep50">
 <bp:stepProcess rdf:resource="#Catalysis15" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction42" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep51">
 <bp:stepProcess rdf:resource="#Catalysis16" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction43" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep58">
 <bp:stepProcess rdf:resource="#Catalysis18" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction47" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep59">
 <bp:stepProcess rdf:resource="#BiochemicalReaction48" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep56">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep57">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep65">
 <bp:stepProcess rdf:resource="#BiochemicalReaction53" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis34">
 <bp:controlled rdf:resource="#BiochemicalReaction82" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep66">
 <bp:stepProcess rdf:resource="#Catalysis21" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction54" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis33">
 <bp:controlled rdf:resource="#BiochemicalReaction80" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep63">
 <bp:stepProcess rdf:resource="#BiochemicalReaction52" />
 <bp:stepProcess rdf:resource="#Catalysis20" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis32">
 <bp:controlled rdf:resource="#BiochemicalReaction78" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep64">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis31">
 <bp:controlled rdf:resource="#BiochemicalReaction76" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep61">
 <bp:stepProcess rdf:resource="#Catalysis19" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction50" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis30">
 <bp:controlled rdf:resource="#BiochemicalReaction74" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep62">
 <bp:stepProcess rdf:resource="#BiochemicalReaction51" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep60">
 <bp:stepProcess rdf:resource="#BiochemicalReaction49" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis29">
 <bp:controlled rdf:resource="#BiochemicalReaction72" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis28">
 <bp:controlled rdf:resource="#BiochemicalReaction70" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep69">
 <bp:stepProcess rdf:resource="#BiochemicalReaction56" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis27">
 <bp:controlled rdf:resource="#BiochemicalReaction69" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis26">
 <bp:controlled rdf:resource="#BiochemicalReaction66" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep67">
 <bp:stepProcess rdf:resource="#Pathway14" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis25">
 <bp:controlled rdf:resource="#BiochemicalReaction64" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep68">
 <bp:stepProcess rdf:resource="#Catalysis22" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction55" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis24">
 <bp:controlled rdf:resource="#BiochemicalReaction63" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep76">
 <bp:stepProcess rdf:resource="#Catalysis24" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction63" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep77">
 <bp:stepProcess rdf:resource="#Catalysis25" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction64" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep74">
 <bp:stepProcess rdf:resource="#BiochemicalReaction61" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep75">
 <bp:stepProcess rdf:resource="#BiochemicalReaction62" />
 <bp:stepProcess rdf:resource="#Catalysis23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep72">
 <bp:stepProcess rdf:resource="#BiochemicalReaction59" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis41">
 <bp:controlled rdf:resource="#BiochemicalReaction96" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep73">
 <bp:stepProcess rdf:resource="#BiochemicalReaction60" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis40">
 <bp:controlled rdf:resource="#BiochemicalReaction93" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep70">
 <bp:stepProcess rdf:resource="#BiochemicalReaction57" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep71">
 <bp:stepProcess rdf:resource="#BiochemicalReaction58" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis39">
 <bp:controlled rdf:resource="#BiochemicalReaction92" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis38">
 <bp:controlled rdf:resource="#BiochemicalReaction89" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis37">
 <bp:controlled rdf:resource="#BiochemicalReaction87" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep78">
 <bp:stepProcess rdf:resource="#Pathway15" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis36">
 <bp:controlled rdf:resource="#BiochemicalReaction84" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep79">
 <bp:stepProcess rdf:resource="#BiochemicalReaction65" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis35">
 <bp:controlled rdf:resource="#BiochemicalReaction83" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR4 mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR4 Y367C mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction90">
 <bp:evidence rdf:resource="#Evidence110" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-BCR-pFGFR1 binds GRB2:GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction91">
 <bp:evidence rdf:resource="#Evidence111" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of cytosolic FGFR1 fusion proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR4 mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction92">
 <bp:evidence rdf:resource="#Evidence112" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of BCR moiety of BCR-FGFR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction93">
 <bp:evidence rdf:resource="#Evidence113" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of cytosolic FGFR1 fusion dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction94">
 <bp:evidence rdf:resource="#Evidence114" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tyrosine kinase inhibitors bind and inhibit cytosolic FGFR1 fusion dimer phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction95">
 <bp:evidence rdf:resource="#Evidence115" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCR-FGFR1 fusion:GRB2:p-GAB2:PIK3R1 binds PIK3CA </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction96">
 <bp:evidence rdf:resource="#Evidence116" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants and fusions phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction97">
 <bp:evidence rdf:resource="#Evidence117" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y-PLCG1 dissociates from activated FGFR4 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction98">
 <bp:evidence rdf:resource="#Evidence118" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction99">
 <bp:evidence rdf:resource="#Evidence119" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y- PLCG1 dissociates from activated FGFR1 mutants and fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence101">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence102">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence103">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence104">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence100">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence109">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence105">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence106">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence107">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence108">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction80">
 <bp:evidence rdf:resource="#Evidence99" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent phosphorylation of overexpressed FGFR1c</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction81">
 <bp:evidence rdf:resource="#Evidence100" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of overexpressed FGFR1c</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction82">
 <bp:evidence rdf:resource="#Evidence102" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCR-FGFR1-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction83">
 <bp:evidence rdf:resource="#Evidence103" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR1OP-FGFR1 phosphorylates STAT1 and STAT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction84">
 <bp:evidence rdf:resource="#Evidence104" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-BCR-p-FGFR1 phosphorylates GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
 <bp:stepProcess rdf:resource="#Catalysis5" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction85">
 <bp:evidence rdf:resource="#Evidence105" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic FGFR1 fusion proteins bind PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction86">
 <bp:evidence rdf:resource="#Evidence106" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCR-FGFR1:GRB2:p-GAB2 binds PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction87">
 <bp:evidence rdf:resource="#Evidence107" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of STAT5 by cytosolic FGFR1 fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction88">
 <bp:evidence rdf:resource="#Evidence108" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated cytosolic FGFR1 fusions bind PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction89">
 <bp:evidence rdf:resource="#Evidence109" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic FGFR1 fusion protein-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
 <bp:stepProcess rdf:resource="#Catalysis7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#Catalysis6" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
 <bp:stepProcess rdf:resource="#Catalysis8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction22" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#BiochemicalReaction23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#BiochemicalReaction20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#BiochemicalReaction21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#Catalysis1" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#Catalysis2" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep32">
 <bp:stepProcess rdf:resource="#BiochemicalReaction26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#Catalysis3" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep33">
 <bp:stepProcess rdf:resource="#BiochemicalReaction27" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#BiochemicalReaction24" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#Catalysis4" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#BiochemicalReaction25" />
 <bp:stepProcess rdf:resource="#Catalysis9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep38">
 <bp:stepProcess rdf:resource="#BiochemicalReaction30" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep39">
 <bp:stepProcess rdf:resource="#BiochemicalReaction31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep36">
 <bp:stepProcess rdf:resource="#BiochemicalReaction29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep37">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep34">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep35">
 <bp:stepProcess rdf:resource="#BiochemicalReaction28" />
 <bp:stepProcess rdf:resource="#Catalysis10" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive dimerization of FGFR4 Y367C mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 kinase mutants are inhibited by PD170734</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep105">
 <bp:stepProcess rdf:resource="#BiochemicalReaction86" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep104">
 <bp:stepProcess rdf:resource="#BiochemicalReaction85" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep103">
 <bp:stepProcess rdf:resource="#Catalysis36" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction84" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep102">
 <bp:stepProcess rdf:resource="#BiochemicalReaction83" />
 <bp:stepProcess rdf:resource="#Catalysis35" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep101">
 <bp:stepProcess rdf:resource="#BiochemicalReaction82" />
 <bp:stepProcess rdf:resource="#Catalysis34" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep100">
 <bp:stepProcess rdf:resource="#Pathway20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep109">
 <bp:stepProcess rdf:resource="#BiochemicalReaction90" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep108">
 <bp:stepProcess rdf:resource="#Catalysis38" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction89" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep107">
 <bp:stepProcess rdf:resource="#BiochemicalReaction88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep106">
 <bp:stepProcess rdf:resource="#Catalysis37" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction87" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep116">
 <bp:stepProcess rdf:resource="#BiochemicalReaction97" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep115">
 <bp:stepProcess rdf:resource="#BiochemicalReaction96" />
 <bp:stepProcess rdf:resource="#Catalysis41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep114">
 <bp:stepProcess rdf:resource="#BiochemicalReaction95" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep113">
 <bp:stepProcess rdf:resource="#BiochemicalReaction94" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep112">
 <bp:stepProcess rdf:resource="#BiochemicalReaction93" />
 <bp:stepProcess rdf:resource="#Catalysis40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep111">
 <bp:stepProcess rdf:resource="#Catalysis39" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction92" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep110">
 <bp:stepProcess rdf:resource="#BiochemicalReaction91" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep118">
 <bp:stepProcess rdf:resource="#BiochemicalReaction99" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep117">
 <bp:stepProcess rdf:resource="#BiochemicalReaction98" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction30">
 <bp:evidence rdf:resource="#Evidence39" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Point mutants of FGFR2 bind and are inactivated by tyrosine kinase inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction31">
 <bp:evidence rdf:resource="#Evidence40" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2c mutants bind an expanded range of ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction32">
 <bp:evidence rdf:resource="#Evidence41" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2b mutants with enhanced ligand binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction33">
 <bp:evidence rdf:resource="#Evidence42" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2 ligand-independent  mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction34">
 <bp:evidence rdf:resource="#Evidence43" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction35">
 <bp:evidence rdf:resource="#Evidence44" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2b mutants bind an expanded range of ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction36">
 <bp:evidence rdf:resource="#Evidence45" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR2 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction26">
 <bp:evidence rdf:resource="#Evidence33" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of overexpressed FGFR2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction27">
 <bp:evidence rdf:resource="#Evidence34" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction28">
 <bp:evidence rdf:resource="#Evidence36" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 fusions autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction29">
 <bp:evidence rdf:resource="#Evidence37" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 fusions dimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction20">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction21">
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y-PLCG1 dissociates from activated FGFR2 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction22">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2IIIa TM binds ligand and full length receptors to inhibit signaling</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction23">
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant alternative splicing yields a secreted FGFR2 IIIa TM disease variant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction24">
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GP369 inhibits activation of amplified FGFR2 signaling</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction25">
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of overexpressed FGFR2 variants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction50">
 <bp:evidence rdf:resource="#Evidence62" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3c P250R mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction51">
 <bp:evidence rdf:resource="#Evidence63" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3c P250R mutant binds to ligand with enhanced affinity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction52">
 <bp:evidence rdf:resource="#Evidence64" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction53">
 <bp:evidence rdf:resource="#Evidence66" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR3 t(4;14) translocation mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction54">
 <bp:evidence rdf:resource="#Evidence67" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 t(4;14) translocation mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction55">
 <bp:evidence rdf:resource="#Evidence69" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction56">
 <bp:evidence rdf:resource="#Evidence70" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3 fusions dimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction57">
 <bp:evidence rdf:resource="#Evidence71" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction58">
 <bp:evidence rdf:resource="#Evidence72" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction48">
 <bp:evidence rdf:resource="#Evidence60" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR3 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction49">
 <bp:evidence rdf:resource="#Evidence61" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive dimerization of FGFR3 cysteine mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction40">
 <bp:evidence rdf:resource="#Evidence49" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction41">
 <bp:evidence rdf:resource="#Evidence50" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction42">
 <bp:evidence rdf:resource="#Evidence51" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction43">
 <bp:evidence rdf:resource="#Evidence52" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction44">
 <bp:evidence rdf:resource="#Evidence54" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction45">
 <bp:evidence rdf:resource="#Evidence55" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction46">
 <bp:evidence rdf:resource="#Evidence56" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3 mutants bind and are inactivated by tyrosine kinase inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction47">
 <bp:evidence rdf:resource="#Evidence59" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 cysteine mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction37">
 <bp:evidence rdf:resource="#Evidence46" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction38">
 <bp:evidence rdf:resource="#Evidence47" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2c mutants with enhanced ligand binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction39">
 <bp:evidence rdf:resource="#Evidence48" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR2 ligand-independent mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction70">
 <bp:evidence rdf:resource="#Evidence85" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction71">
 <bp:evidence rdf:resource="#Evidence88" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Plasma membrane FGFR1 fusions dimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction72">
 <bp:evidence rdf:resource="#Evidence89" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Plasma membrane FGFR1 fusions autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction73">
 <bp:evidence rdf:resource="#Evidence91" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR1 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction74">
 <bp:evidence rdf:resource="#Evidence92" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR1 mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction75">
 <bp:evidence rdf:resource="#Evidence93" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR1c P252X mutants bind ligand with enhanced affinity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction76">
 <bp:evidence rdf:resource="#Evidence94" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR1c P252X mutant dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction77">
 <bp:evidence rdf:resource="#Evidence96" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of overexpressed FGFR1b</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction78">
 <bp:evidence rdf:resource="#Evidence97" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent phosphorylation of overexpressed FGFR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction79">
 <bp:evidence rdf:resource="#Evidence98" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tyrosine kinase inhibitors bind and inhibit overexpressed FGFR1 dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction60">
 <bp:evidence rdf:resource="#Evidence74" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y-PLCG1 dissociates from activated FGFR3 point and translocation mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction61">
 <bp:evidence rdf:resource="#Evidence75" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point and translocation mutants bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction62">
 <bp:evidence rdf:resource="#Evidence76" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction63">
 <bp:evidence rdf:resource="#Evidence77" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point and translocation mutants phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction64">
 <bp:evidence rdf:resource="#Evidence78" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction65">
 <bp:evidence rdf:resource="#Evidence80" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction66">
 <bp:evidence rdf:resource="#Evidence81" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction67">
 <bp:evidence rdf:resource="#Evidence82" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants and fusions bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction68">
 <bp:evidence rdf:resource="#Evidence83" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction69">
 <bp:evidence rdf:resource="#Evidence84" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction59">
 <bp:evidence rdf:resource="#Evidence73" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence112">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence113">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence114">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence115">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence110">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence111">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence116">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence117">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence118">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence119">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep37" />
 <bp:pathwayOrder rdf:resource="#PathwayStep34" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autosomal dominant mutations in FGFR2 are associated with the development of a range of skeletal disorders including Beare-Stevensen cutis gyrata syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome, Crouzon syndrome and Apert Syndrome (reveiwed in Burke, 1998; Webster and Donoghue 1997; Cunningham, 2007).  Activating point mutations have also been identified in FGFR2 in ~15% of endometrial cancers, as well as to a lesser extent in ovarian and gastric cancers (Dutt, 2008; Pollock, 2007; Byron, 2010; Jang, 2001).  Activating mutations in FGFR2 are thought to contribute to receptor activation through diverse mechanisms, including constitutive ligand-independent dimerization (Robertson, 1998), expanded range and affinity for ligand (Ibrahimi, 2004b; Yu, 2000) and enhanced kinase activity (Byron, 2008; Chen, 2007).  FGFR2 amplifications have been identified in 10% of gastric cancers, where they are associated with poor prognosis diffuse cancers (Hattori, 1996; Ueda, 1999; Shin, 2000; Kunii, 2008) , and in ~1% of breast cancers (Turner, 2010; Tannheimer, 2000).   FGFR2 amplification often occur in conjunction with deletions of C-terminal exons, resulting in expression of a internalization- and degradation-resistant form of the receptor (Takeda, 2007; Cha, 2008, 2009). Signaling through overexpressed FGFR2 shows evidence of being ligand-independent and sensitive to FGFR inhibitors  (Lorenzi, 1997; Takeda, 2007; Cha, 2009). More recently, FGFR2 fusion proteins have been identified in a number of cancers; these are thought to form constitutive ligand-independent dimers based on the dimerization domains of the 3&apos; fusion partners and contribute to cellular proliferation and tumorigenesis in a kinase-inhibitor sensitive manner (Wu, 2013; Arai, 2013; Seo, 2012; reviewed in Parker, 2014). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence90">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction22" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction23" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 IIIa TM</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A soluble truncated form of FGFR2 is aberrantly expressed in an Apert Syndrome mouse model and inhibits FGFR signaling in vitro and in vivo.  This variant, termed FGFR IIIa TM, arises from an misspliced transcript that fuses exon 7 to exon 10 and that escapes nonsense-mediated decay.  FGFR2 IIIa TM may inhibit signaling by sequestering FGF ligand and/or by forming nonfunctional heterodimers with full-length receptors at the cell surface (Wheldon et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 is perhaps the least well studied of the FGF receptors, and unlike the case for the other FGFR genes, mutations in FGFR4 are not known to be associated with any developmental disorders.  Recently, however, somatically arising mutations in the FGFR4 coding sequence have begun to be identified in some cancers.  (Taylor, 2009; Ruhe, 2007; Roidl, 2010).  The resulting mutant versions of FGFR4 promote aberrant signaling through ligand-independent dimerization and enhanced autophosphorylation, among other mechanisms (Roidl, 2009; Taylor, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence92">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayOrder rdf:resource="#PathwayStep49" />
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayOrder rdf:resource="#PathwayStep48" />
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep50" />
 <bp:pathwayOrder rdf:resource="#PathwayStep51" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction40" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction41" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction20" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction42" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction43" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR2 gene has been shown to be subject to activating mutations and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically.  Activating FGFR2 mutations in the germline give rise to a range of craniosynostotic conditions including Pfeiffer, Apert, Jackson-Weiss, Crouzon and Beare-Stevensen Cutis Gyrata syndromes.  These autosomal dominant skeletal disorders are characterized by premature fusion of several sutures in the skull, and in some cases also involve syndactyly (abnormal bone fusions in the hands and feet) (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007).   Activating FGFR2 mutations arising somatically have been linked to the development of gastric and endometrial cancers (reviewed in Greulich and Pollock, 2011; Wesche, 2011).  Many of these mutations are similar or identical to those that contribute to the autosomal disorders described above.  Notably, loss-of-function mutations in FGFR2 have also been recently described in melanoma (Gartside, 2009).  FGFR2 may also contribute to tumorigenesis through overexpression, as FGFR2 has been identified as a target of gene amplification in gastric and breast cancers (Kunii, 2008; Takeda, 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence91">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep38" />
 <bp:pathwayOrder rdf:resource="#PathwayStep39" />
 <bp:pathwayOrder rdf:resource="#PathwayStep47" />
 <bp:pathwayOrder rdf:resource="#PathwayStep45" />
 <bp:pathwayOrder rdf:resource="#PathwayStep46" />
 <bp:pathwayOrder rdf:resource="#PathwayStep43" />
 <bp:pathwayOrder rdf:resource="#PathwayStep44" />
 <bp:pathwayOrder rdf:resource="#PathwayStep41" />
 <bp:pathwayOrder rdf:resource="#PathwayStep42" />
 <bp:pathwayOrder rdf:resource="#PathwayStep40" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction37" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction38" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction30" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction32" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction33" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction34" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction36" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence38" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated point mutants of FGFR2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autosomal dominant mutations in FGFR2 are associated with the development of a range of skeletal disorders including Beare-Stevensen cutis gyrata syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome, Crouzon syndrome and Apert Syndrome (reveiwed in Burke, 1998; Webster and Donoghue 1997; Cunningham, 2007).  Mutations that give rise to Crouzon, Jackson-Weiss and Pfeiffer syndromes tend to cluster in the third Ig-like domain of the receptor, either in exon IIIa (shared by the IIIb and the IIIc isoforms) or in the FGFR2c-specific exon IIIc.  These mutations frequently involve creation or removal of a cysteine residue, leading to the formation of an unpaired cysteine residue that is thought to promote intramolecular dimerization and thus constitutive, ligand-independent activation (reviewed in Burke, 1998; Webster and Donoghue, 1997; Cunningham, 2007).  Mutations in FGFR2 that give rise to Apert Syndrome cluster to the highly conserved Pro-Ser dipeptide in the IgII-Ig III linker; mutations in the paralogous residues of FGFR1 and 3 give rise to Pfeiffer and Muenke syndromes, respectively (Muenke, 1994; Wilkie, 1995; Bellus, 1996). Development of Beare-Stevensen cutis gyrata is associated with mutations in the transmembrane-proximal region of the receptor (Przylepa, 1996), and similar mutations in FGFR3 are linked to the development of thanatophoric dysplasia I (Tavormina, 1995a).  These mutations all affect FGFR2 signaling without altering the intrinsic kinase activity of the receptor.   Activating point mutations have also been identified in FGFR2 in ~15% of endometrial cancers, as well as to a lesser extent in ovarian and gastric cancers (Dutt, 2008; Pollock, 2007; Byron, 2010; Jang, 2001).  These mutations are found largely in the extracellular region and in the kinase domain of the receptor, and parallel activating mutations seen in autosomal dominant disorders described above.   Activating mutations in FGFR2 are thought to contribute to receptor activation through diverse mechanisms, including constitutive ligand-independent dimerization (Robertson, 1998), expanded range and affinity for ligand (Ibrahimi, 2004b; Yu, 2000) and enhanced kinase activity (Byron, 2008; Chen, 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep32" />
 <bp:pathwayOrder rdf:resource="#PathwayStep33" />
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction26" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction24" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction25" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 amplification mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 amplifications have been identified in 10% of gastric cancers, where they are associated with poor prognosis diffuse cancers (Hattori, 1996; Ueda, 1999; Shin, 2000; Kunii, 2008) , and in ~1% of breast cancers (Turner, 2010; Tannheimer, 2000).   FGFR2 amplification often occur in conjunction with deletions of C-terminal exons, resulting in expression of a internalization- and degradation-resistant form of the receptor (Takeda, 1999; Cha, 2008, 2009). Amplification affects signaling without altering the intrinsic kinase activity of the receptor. Signaling through overexpressed FGFR2 also shows evidence of being ligand-independent and sensitive to FGFR inhibitors  (Lorenzi, 1997; Takeda, 1999; Cha, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep36" />
 <bp:pathwayOrder rdf:resource="#PathwayStep35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction29" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence35" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 fusions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 fusions have been identified in cancers such as lung, breast, thyroid and cholangiocarcinoma (Wu et al, 2013; Seo et al, 2012; Arai et al, 2013).  Of all the FGF receptors, FGFR2 shows the broadest range of 3&apos; fusion partners, including BICC1, AHCYL1, CIT, CCDC6, CASP7, AFF3, OFD1 and CCAR2.  Many of these fusion partners contain dimerization domains, suggesting that the resulting fusions may demonstrate constitutive ligand-independent activation (Wu et al, 2013; Arai et al, 2013; Seo et al, 2012; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence98">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence97">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence99">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence94">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence93">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence96">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence95">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep78" />
 <bp:pathwayOrder rdf:resource="#PathwayStep52" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway15" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A number of skeletal and developmental diseases have been shown to arise as a result of mutations in the FGFR1, 2 and 3 genes.  These include dwarfism syndromes (achondroplasia, hypochondroplasia and the neonatal lethal disorders thanatophoric dysplasia I and II), as well as craniosynostosis disorders such as Pfeiffer, Apert, Crouzon, Jackson-Weiss and Muenke syndromes (reviewed in Webster and Donoghue 1997; Burke, 1998, Cunningham, 2007; Harada, 2009).  These mutations fall into four general regions of the receptor: a) the immunoglobulin (Ig)-like domain II-III linker region,  b) the alternatively spliced second half of the Ig III domain, c) the transmembrane domain and d) the tyrosine kinase domain (reviewed in Webster and Donoghue, 1997).  With the exception of mutations in class b), which affect only the relevant splice variant, these mutations may be present in either the &apos;b&apos; or &apos;c&apos; isoforms. These activating mutations affect FGFR function by altering or expanding the ligand-binding range of the receptors (see for instance Ibrahimi, 2004a), by promoting ligand-independent dimerization (for instance, Galvin,1996; Neilson and Friesel, 1996; d&apos;Avis,1998) or by increasing the activity of the kinase domain (for instance, Webster, 1996; Naski, 1996; Tavormina, 1999; Bellus, 2000).  Thus, a number of the point mutations found in FGFR receptors alter their activity without altering their intrinsic kinase activity.  Many of the mutations that promote constitutive dimerization do so by creating or removing cysteine residues; the presence of an unpaired cysteine in the receptor is believed to promote dimerization through the formation of intramolecular disulphide bonds (Galvin, 1996; Robertson, 1998). Paralogous mutations at equivalent positions have been identified in more than one FGF receptor, sometimes giving rise to different diseases.  For instance, mutation of the highly conserved FGFR2 Ser252-Pro253 dipeptide in the region between the second and third Ig domain is responsible for virtually all cases of Apert Syndrome (Wilkie, 1995), while paralogous mutations in FGFR1 (S252R) and FGFR3 (P250R) are associated with Pfeiffer and Crouzon syndromes, respectively (Bellus, 1996).  FGFR4 is unique in that mutations of this gene are not known to be associated with any developmental disorders.  Recently, many of the same activating mutations in the FGFR genes that have been characterized in skeletal and developmental disorders have begun to be identified in a range of cancers (reviewed in  Turner and Gross, 2010; Greulich and Pollock, 2011; Wesche, 2011).  The best established link between a somatic mutation of an FGFR and the development of cancer is in the case of FGFR3, where 50% of bladder cancers have mutations in the FGFR3 coding sequence.  Of these mutations, which largely match the activating mutations seen in thanatophoric dysplasias, over half occur at a single residue (S249C) (Cappellen, 1999; van Rhijn, 2002).  Activating mutations have also been identified in the coding sequences of FGFR1, 2 and 4 (for review, see Wesche, 2011)  In addition to activating point mutations, the FGFR1, 2 and 3 genes are subject to misregulation in cancer through gene amplification and translocation events, which are thought to lead to overexpression and ligand-independent dimerization (Weiss, 2010; Turner, 2010; Kunii, 2008; Takeda, 2007; Chesi, 1997; Avet-Loiseau, 1998; Ronchetti, 2001).  It is important to note, however, that in each of these cases, the amplification or translocation involve large genomic regions encompassing additional genes, and the definitive roles of the FGFR genes in promoting oncogenesis has not been totally established. In the case of FGFR1, translocation events also give rise to FGFR1 fusion proteins that contain the intracellular kinase domain of the receptor fused to a dimerization domain from the partner gene.  These fusions, which are expressed in a pre-leukemic myeloproliferative syndrome, dimerize constitutively based on the dimerization domain provided by the fusion partner and are constitutively active (reviewed in Jackson, 2010).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR4 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 is perhaps the least well studied of the FGF receptors, and unlike the case for the other FGFR genes, mutations in FGFR4 are not known to be associated with any developmental disorders.  Recently, however, somatically arising mutations in the FGFR4 coding sequence have begun to be identified in some cancers.  8% of rhabdomyosarcomas have activating mutations in the kinase domain of FGFR4.  Two of these mutations - N535K (paralogous to the FGFR2 N550K allele found in endometrial cancers) and V550E - have been shown to support the oncogenic transformation of NIH 3T3 cells (Taylor, 2009).  An FGFR4 Y367C mutation has also been identified in breast cancers (Ruhe, 2007; Roidl, 2010); mutations of paralogous residues in FGFR2 and FGFR3 are associated with both skeletal dysplasias and the development of diverse cancers (Pollock, 2007; Ruhe, 2007; Rousseau, 1996; Chesi, 1997, 2001).   Finally, a SNP at position 388 of FGFR4 is associated with aggressive disease development.  Expression of the G388R allele in breast, colorectal and prostate cancers is correlated with rapid progression times and increased rates of recurrence and metastasis (Bange, 2002; Spinola, 2005; Wang, 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence70">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence76">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence75">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence78">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence77">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence72">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence71">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence74">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence73">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence69">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence68">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence81">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence80">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence87">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence86">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence89">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence88">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence83">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence82">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence85">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence84">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence79">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence54">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence53">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence56">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence55">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence50">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence52">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence51">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence47">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence46">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence49">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence48">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence65">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence64">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence67">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence66">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence61">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence60">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence63">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence62">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence58">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence57">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence59">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence34">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence33">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway18">
 <bp:pathwayOrder rdf:resource="#PathwayStep90" />
 <bp:pathwayOrder rdf:resource="#PathwayStep91" />
 <bp:pathwayOrder rdf:resource="#PathwayStep92" />
 <bp:pathwayOrder rdf:resource="#PathwayStep93" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction73" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction74" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction75" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction76" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence90" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by activated point mutants of FGFR1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unlike FGFR2 and FGFR3, FGFR1 appears not to be a frequent target of activating point mutations (reviewed in Wesche, 2011; Turner and Grose, 2010).  Germline point mutations at residue P252 have been identified in Pfeiffer syndrome (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007) while mutation of the same residue arising somatically has been identified in melanoma and lung cancer (Ruhe, 2007; Davies, 2005).  Two kinase domain mutations have been characterized in glioblastoma (Rand, 2005; Network TCGA, 2008), both at positions that are also mutated in an autosomal disorder in one of the FGFR family members (Muenke, 1994; Bellus, 1995a; Bellus, 2000; Tavormina, 1995a; Tavormina, 1999).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway19">
 <bp:pathwayOrder rdf:resource="#PathwayStep98" />
 <bp:pathwayOrder rdf:resource="#PathwayStep99" />
 <bp:pathwayOrder rdf:resource="#PathwayStep96" />
 <bp:pathwayOrder rdf:resource="#PathwayStep97" />
 <bp:pathwayOrder rdf:resource="#PathwayStep95" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction80" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction81" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction77" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction78" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction79" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence95" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR1 amplification mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Amplification or activation of FGFR1 has been reported in  lung cancer (Weiss, 2001; Marek, 2009; Dutt, 2011), breast cancer (Reis-Filho, 2006; Turner, 2010), oral squamous carcinoma (Freier, 2007), esophageal squamous cell carcinomas (Ishizuka, 2002), ovarian cancer (Gorringe, 2007), bladder cancer (Simon, 2001), prostate cancer (Edwards, 2003; Acevedo, 2007) and rhabodomyosarcoma (Missiaglia, 2009).  Unlike the case for FGFR2 amplifications, FGFR1 amplifications are not associated with additional point mutations and affect signaling without altering the intrinsic kinase activity of the receptor.  Overexpressed FGFR1 appears to signal at a basal level in a ligand-independent fashion, but is also able to be stimulated by exogenous ligand.  Downstream activation may be the result of aberrant paracrine or autocrine stimulation (reviewed in Turner and Gross, 2010; Greulich and Pollock, 2011).  FGFR1 amplification has not been conclusively demonstrated to be the causative oncogenic agent in all of the cancer types mentioned above, and other genes in the 8p11 region may also be candidates in some cases (Bass, 2009; Bernard-Pierrot, 2008; Ray, 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway16">
 <bp:pathwayOrder rdf:resource="#PathwayStep100" />
 <bp:pathwayOrder rdf:resource="#PathwayStep89" />
 <bp:pathwayOrder rdf:resource="#PathwayStep86" />
 <bp:pathwayOrder rdf:resource="#PathwayStep94" />
 <bp:pathwayComponent rdf:resource="#Pathway18" />
 <bp:pathwayComponent rdf:resource="#Pathway19" />
 <bp:pathwayComponent rdf:resource="#Pathway17" />
 <bp:pathwayComponent rdf:resource="#Pathway20" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence86" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR1 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR1 gene has been shown to be subject to activating mutations, chromosomal rearrangements and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007; Wesche, 2011; Greulich and Pollock, 2011). Many of the resulting mutant FGFR1 proteins can dimerize and promote signaling in a ligand-independent fashion, although signal transduction may still be amplified in the presence of ligand (reviewed in Turner and Gross, 2010; Greulich and Pollock, 2011; Wesche et al, 2011).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway17">
 <bp:pathwayOrder rdf:resource="#PathwayStep87" />
 <bp:pathwayOrder rdf:resource="#PathwayStep88" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction72" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence87" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by plasma membrane FGFR1 fusions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to the cytosolic FGFR1 fusions identified in 8 myeloproliferative syndrome, plasma membrane localized FGFR1 fusions have been identified in glioblastoma, breast cancer and non small cell lung cancers (Singh et al, 2012; Wu et al, 2013; Wang et al, 2014).  A FGFR1:TACC1 fusion identified in glioblastoma promotes anchorage independent growth when expressed in Rat1A cells, while an ERLIN2:FGFR1 fusion in breast cancer shows constitutive autophosphorylation when expressed in HEK 293 cells (Singh et al, 2012; Wu et al, 2013).  All FGFR1 fusions tested also shown increased sensitivity to growth inhibition upon treatment with kinase inhibitors (Singh et al, 2012; Wu et al, 2013; Wang et al, 2014; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep56" />
 <bp:pathwayOrder rdf:resource="#PathwayStep54" />
 <bp:pathwayOrder rdf:resource="#PathwayStep76" />
 <bp:pathwayOrder rdf:resource="#PathwayStep55" />
 <bp:pathwayOrder rdf:resource="#PathwayStep77" />
 <bp:pathwayOrder rdf:resource="#PathwayStep74" />
 <bp:pathwayOrder rdf:resource="#PathwayStep53" />
 <bp:pathwayOrder rdf:resource="#PathwayStep75" />
 <bp:pathwayOrder rdf:resource="#PathwayStep72" />
 <bp:pathwayOrder rdf:resource="#PathwayStep73" />
 <bp:pathwayOrder rdf:resource="#PathwayStep70" />
 <bp:pathwayOrder rdf:resource="#PathwayStep71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction59" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction61" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction62" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction63" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction64" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction44" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction45" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction46" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction57" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction58" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence53" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR3 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR3 gene has been shown to be subject to activating mutations and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically.    Activating mutations in FGFR3 are associated with the development of a range of skeletal dysplasias that result in dwarfism (reviewed in Webster and Donoghue, 1997; Burke et al, 1998; Harada et al, 2009).  The most common form of human dwarfism is achondroplasia (ACH), which is caused by mutations G380R and G375C in the transmembrane domain of FGFR3 that are thought to promote ligand-independent dimerization (Rousseau et al, 1994; Shiang et al, 1994; Bellus et al, 1995a)  Hypochondroplasia (HCH) is a milder form dwarfism that is the result of mutations in the tyrosine kinase domain of FGFR3 (Bellus et al, 1995b).  Two neonatal lethal conditions, thanatophoric dysplasia type I and II (TDI and TDII) are also the result of mutations in FGFR3; TDI arises from a range of mutations that either result in the formation of unpaired cysteine residues in the extracellular region that promote aberrant ligand-independent dimerization or by mutations that introduce stop codons (Rousseau et al, 1995; Rousseau et al, 1996, D&apos;Avis et al,1998).  A single mutation, K650E in the second tyrosine kinase domain of FGFR3 is responsible for all identified cases of TDII (Tavormina et al, 1995a, b).  Other missense mutations at the same K650 residue give rise to Severe Achondroplasia with Developmental Disorders and Acanthosis Nigricans (SADDAN) syndrome (Tavormina et al, 1999; Bellus et al, 1999).   The severity of the phenotype arising from many of the activating FGFR3 mutations has recently been shown to correlate with the extent to which the mutations activate the receptor (Naski et al, 1996; Bellus et al, 2000)   In addition to mutations that cause dwarfism syndromes, a Pro250Arg mutation in the conserved dipeptide between the IgII and IgIII domains has been identified in an atypical craniosynostosis condition (Bellus et al, 1996; Reardon et al, 1997).  This mutation, which is paralogous to mutations seen in FGFR1 and 2 in Pfeiffer and Apert Syndrome, respectively, results in an increase in ligand-binding affinity for the receptor (Ibrahimi et al, 2004b).   Of all the FGF receptors, FGFR3 has perhaps the best established link to the development in cancer.  50% of bladder cancers have somatic mutations in the coding sequence of FGFR3; of these, more than half occur in the extracellular region at a single position (S249C) (Cappellen et al, 1999; Naski et al, 1996; di Martino et al, 2009, Sibley et al, 2001).  Activating mutations are also seen in the juxta- and trans-membrane domains, as well as in the kinase domain (reviewed in Weshe et al, 2011).  As is the case for the other receptors, many of the activating mutations that are seen in FGFR3-related cancers mimic the germline FGFR3 mutations that give rise to autosomal skeletal disorders and include both ligand-dependent and independent mechanisms (reviewed in Webster and Donoghue, 1997; Burke et al, 1998). In addition to activating mutations, the FGFR3 gene is subject to a translocation event in 15% of multiple myelomas (Avet-Loiseau et al, 1998; Chesi et al, 1997).  This chromosomal rearrangement puts the FGFR3 gene under the control of the highly active IGH promoter and promotes overexpression and constitutive activation of FGFR3.  In a small proportion of multiple myelomas, the translocation event is accompanied by activating mutations in the FGFR3 coding sequence (Chesi et al, 1997).  More recently, a number of fusion proteins of FGFR3 have been identified in various cancers (Singh et al, 2012; Williams et al, 2013; Parker et al, 2013; Wu et al, 2013; Wang et al, 2014; Yuan et al, 2014; reviewed in Parker et al, 2014). The most common fusion protein is TACC3, a coiled coil protein involved in mitotic spindle assembly.  FGFR3 fusion proteins are constitutively active and appear to contribute to proliferation and tumorigenesis through activation of the ERK and AKT signaling pathways (reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep67" />
 <bp:pathwayOrder rdf:resource="#PathwayStep57" />
 <bp:pathwayOrder rdf:resource="#PathwayStep64" />
 <bp:pathwayComponent rdf:resource="#Pathway14" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence57" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR3 gene has been shown to be subject to activating mutations and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically.  As is the case for the other receptors, many of the activating mutations that are seen in FGFR3-related cancers mimic the germline FGFR3 mutations that give rise to autosomal skeletal disorders and include both ligand-dependent and independent mechanisms (reviewed in Webster and Donoghue, 1997; Burke et al, 1998; Wesche et al, 2011). In addition to activating mutations, the FGFR3 gene is subject to a translocation event in 15% of multiple myelomas (Avet-Loiseau et al, 1998; Chesi et al, 1997). This chromosomal rearrangement puts the FGFR3 gene under the control of the highly active IGH promoter and promotes overexpression and constitutive activation of FGFR3 (Otsuki et al, 1999).  In a small proportion of multiple myelomas, the translocation event is accompanied by activating mutations in the FGFR3 coding sequence (Chesi et al, 1997; Onwuazor et al, 2003; Ronchetti et al, 2001). Finally, FGFR3 is subject to fusion events in a number of cancers, including lung, bladder and glioblastoma (Singh et al, 2012; Parker et al, 2013; Williams et al, 2013; Wu et al, 2013; Capelletti et al, 2014; Yuan et al, 2014; Wang et al, 2014; Carneiro et al, 2015; reviewed in Parker et al, 2014). These fusions are constitutively active based on dimerization domains provided by the fusion partners and support transformation and proliferation through downstream signaling pathways such as ERK and AKT (Singh et al, 2012; Williams et al, 2013; Parker et al, 2013; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway14">
 <bp:pathwayOrder rdf:resource="#PathwayStep69" />
 <bp:pathwayOrder rdf:resource="#PathwayStep68" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction55" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction56" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence68" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR3 fusions in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In recent years, recurrent fusions of FGFR3 have been identified in a number of cancers, including glioblastoma and cancers of the lung and bladder, among others (Singh et al, 2012; Parker et al, 2013; Williams et al, 2013; Wu et al, 2013; Capelletti et al, 2014; Yuan et al, 2014; Wang et al, 2014; Carneiro et al, 2015; reviewed in Parker et al, 2014). The most common fusion partner of FGFR3 is TACC3 (transforming acidic coiled coil protein 3), a protein involved in mitotic spindle assembly and chromosome segregation (Lin et al, 2010; Burgess et al, 2015).  FGFR3 fusions are constitutively active and may form oligomers in a ligand-independent manner based on dimerization domains provided by the fusion partner (Singh et al, 2012; Williams et al, 2013; Parker et al, 2013; reviewed in Parker et al, 2014). Transformation and proliferation appear to be promoted through activation of the ERK and AKT signaling pathways. In contrast, PLC gamma signaling is not stimulated downstream of FGFR3 fusions, as the PLC gamma docking site is not present in the fusion.  FGFR3 fusions are sensitive to protein kinase inhibitors, suggesting their potential as therapeutic targets (Singh et al, 2012; Williams et al, 2013; Wu et al, 2013; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway15">
 <bp:pathwayOrder rdf:resource="#PathwayStep116" />
 <bp:pathwayOrder rdf:resource="#PathwayStep80" />
 <bp:pathwayOrder rdf:resource="#PathwayStep115" />
 <bp:pathwayOrder rdf:resource="#PathwayStep79" />
 <bp:pathwayOrder rdf:resource="#PathwayStep85" />
 <bp:pathwayOrder rdf:resource="#PathwayStep83" />
 <bp:pathwayOrder rdf:resource="#PathwayStep84" />
 <bp:pathwayOrder rdf:resource="#PathwayStep81" />
 <bp:pathwayOrder rdf:resource="#PathwayStep118" />
 <bp:pathwayOrder rdf:resource="#PathwayStep82" />
 <bp:pathwayOrder rdf:resource="#PathwayStep117" />
 <bp:pathwayComponent rdf:resource="#Pathway16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction70" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction96" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction97" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction65" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction98" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction66" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction99" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction67" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction68" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction69" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence79" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR1 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR1 gene has been shown to be subject to activating mutations, chromosomal rearrangements and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007; Wesche, 2011; Greulich and Pollock, 2011).     Activating mutation P252R in FGFR1 is associated with the development of Pfeiffer syndrome, characterized by craniosynostosis (premature fusion of several sutures in the skull) and broadened thumbs and toes (Muenke, 1994; reviewed in Cunningham, 2007).  This residue falls in a highly conserved Pro-Ser dipeptide between the second and third Ig domains of the extracellular region of the receptor. The mutation is thought to increase the number of hydrogen bonds formed with the ligand and to thereby increase ligand-binding affinity (Ibrahimi, 2004a). Unlike other FGF receptors, few activating point mutations in the FGFR1 coding sequence have been identified in cancer.  Point mutations in the Ig II-III linker analagous to the P252R Pfeiffer syndrome mutation have been identified in lung cancer and melanoma (Ruhe, 2007; Davies, 2005), and two kinase-domain mutations in FGFR1 have been identified in glioblastoma (Rand, 2005, Network TCGA, 2008).  In contrast,  FGFR1 is a target of chromosomal rearrangements in a number of cancers.  FGFR1 has been shown to be recurrently translocated in the 8p11 myeloproliferative syndrome (EMS), a pre-leukemic condition also known as stem cell leukemia/lymphoma (SCLL) that rapidly progresses to leukemia.  This translocation fuses the kinase domain of FGFR1 with the dimerization domain of one of 10 identified fusion partners, resulting in the constitutive dimerization and activation of the kinase (reviewed in Jackson, 2010).    Amplification of the FGFR1 gene has been implicated as a oncogenic factor in a range of cancers, including breast, ovarian, bladder, lung, oral squamous carcinomas, and rhabdomyosarcoma (reviewed in Turner and Grose, 2010; Wesche, 2011; Greulich and Pollock, 2011), although there are other candidate genes in the amplified region and the definitive role of FGFR1 has not been fully established. More recently, FGFR1 fusion proteins have been identified in a number of cancers; these are thought to undergo constitutive ligand-independent dimerization and activation based on dimerization motifs found in the fusion partners (reviewed in Parker, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep58" />
 <bp:pathwayOrder rdf:resource="#PathwayStep59" />
 <bp:pathwayOrder rdf:resource="#PathwayStep63" />
 <bp:pathwayOrder rdf:resource="#PathwayStep61" />
 <bp:pathwayOrder rdf:resource="#PathwayStep62" />
 <bp:pathwayOrder rdf:resource="#PathwayStep60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction48" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction49" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction50" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction51" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction52" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction47" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence58" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by activated point mutants of FGFR3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating point mutations in FGFR3 are found in the extracellular ligand-binding domain, the transmembrane region and the tyrosine kinase domain and are believed to result in ligand-independent activation of the receptor (Webster and Donoghue, 1996; Wenbster, 1997).  These mutations, although initially characterized in the context of autosomal skeletal disorders, are now being identified in a range of cancers including bladder, cervical, breast, prostate, head and neck, and multiple myeloma (reviewed in Wesche, 2011). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep65" />
 <bp:pathwayOrder rdf:resource="#PathwayStep66" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction53" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction54" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence65" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">t(4;14) translocations of FGFR3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translocations which put the FGFR3 gene under the control of the strong IGH promoter have been identified in 15% of multiple myelomas (Avet-Loiseau, 1998; Chesi, 1997; Chesi, 2001).  This translocation, which occurs 70kb upstream of the FGFR3 gene, also involves the nearby multiple myeloma SET-domain containing (MMSET) gene (Lauring, 2008), and although the contribution of each of these genes to the development of cancer has not been fully elucidated, several studies have shown that t(4:14) myeloma cell lines are sensitive to FGFR3 inhibitors (Trudel, 2006; Qing, 2009).  In ~5% of cases, the translocation is accompanied by activating mutations of FGFR3 (Onwuazor, 2003; Ronchetti, 2001).  The t(4;14) translocation results in overexpression of FGFR3 and subsequent ligand independent or anomalous ligand-dependent signaling (Otsuki, 1999).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence43">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence42">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence45">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence44">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence41">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence40">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence39">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence36">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence35">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence38">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence37">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway20">
 <bp:pathwayOrder rdf:resource="#PathwayStep105" />
 <bp:pathwayOrder rdf:resource="#PathwayStep104" />
 <bp:pathwayOrder rdf:resource="#PathwayStep103" />
 <bp:pathwayOrder rdf:resource="#PathwayStep114" />
 <bp:pathwayOrder rdf:resource="#PathwayStep102" />
 <bp:pathwayOrder rdf:resource="#PathwayStep113" />
 <bp:pathwayOrder rdf:resource="#PathwayStep101" />
 <bp:pathwayOrder rdf:resource="#PathwayStep112" />
 <bp:pathwayOrder rdf:resource="#PathwayStep111" />
 <bp:pathwayOrder rdf:resource="#PathwayStep110" />
 <bp:pathwayOrder rdf:resource="#PathwayStep109" />
 <bp:pathwayOrder rdf:resource="#PathwayStep108" />
 <bp:pathwayOrder rdf:resource="#PathwayStep107" />
 <bp:pathwayOrder rdf:resource="#PathwayStep106" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction90" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction91" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction92" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction82" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction93" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction83" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction94" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction84" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction95" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction85" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction86" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction87" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction88" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction89" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence101" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by cytosolic FGFR1 fusion mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">8p11 myeloproliferative syndrome (EMS) is an aggressive disorder that is associated with a translocation event at the FGFR1 gene on chromosome 8p11.  Typical symptoms upon diagnosis include eosinophilia and associated T-cell lymphoblastic lymphoma; the disease rapidly advances to acute leukemia, usually of myeloid lineage.  At present the only effective treatment is allogenic stem cell transplantation (reviewed in Jackson, 2010).    At the molecular level, EMS appears to be caused by translocation events on chromosome 8 that create gene fusions between the intracellular domain of FGFR1 and an N-terminal partner gene that encodes a dimerization domain.  The resulting fusion protein dimerizes in a ligand-independent fashion based the N-terminal domain provided by the partner protein and stimulates constititutive downstream FGFR1 signaling without altering the intrisic kinase activity of the receptor.  To date, 11 partner genes have been identified: ZMYM2, FGFR1OP, FGFR1OP2, HERVK, TRIM24, CUX1, BCR, CEP110, LRRFIP1, MYO18A and CPSF6, although not all have been functionally characterized (reviewed in Jackson, 2010, Turner and Grose, 2010; Wesche, 2011).   Where examined, cell lines carrying FGFR1 fusion genes have been shown to be transforming  and to support IL3-independent proliferation through anti-apoptotic, prosurvival pathways(Lelievre, 2008; Ollendorff, 1999; Chase, 2007; Guasch, 2001; Wasag 2011; Roumiantsev, 2004; Demiroglu, 2001; Smedley, 1999).  Signaling appears to occur predominantly through PLCgamma, PI3K and STAT signaling, with a more minor contribution from MAPK activation.  Because the fusion proteins lack the FRS2-binding site, the mechanism of MAPK activation is unclear.  Recruitment of  GRB2:SOS1 through recruitment of SHC is one possibility (Guasch, 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>
</rdf:RDF>